TMR’S report on the multiple sclerosis drugs market studies the past as well as the current growth trends and opportunities, to gain valuable insights of the same indicators for the market over the forecast period from 2019 to 2027. The report provides the overall market revenue of the multiple sclerosis drugs market for the period 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) of the multiple sclerosis drugs market for the forecast period 2019–2027.
Multiple Sclerosis Drugs Market: Introduction
In terms of revenue, the multiple sclerosis drugs market is projected to expand at a CAGR of ~6% during
the forecast period, due to numerous factors, about which TMR offers comprehensive insights and
forecasts in the global multiple sclerosis drugs market report.
Multiple sclerosis is a central nervous system disorder. It is a potentially disabling disease of the spinal
cord and brain. In multiple sclerosis, the immune system attacks the myelin (protective sheath) that
shields nerve fibers, which causes communication issues between the brain and the rest of the body.
Multiple sclerosis can cause permanent deterioration or damage to the nerves. The cause of multiple
sclerosis is still unknown. Researchers believe that genetic and environmental factors contribute to the
risk of developing multiple sclerosis.
Rise in prevalence and incidence of multiple sclerosis, rapid increase in the geriatric population leading a
surge in cases of multiple sclerosis, and increase in awareness about multiple sclerosis are the major
factors fueling the growth of the multiple sclerosis drugs market.
Request for Report Brochure -
Use of Monoclonal Antibodies for Treatment of Multiple Sclerosis
In terms of drug class, the multiple sclerosis drugs market has been segmented into interferon beta,
sphingosine 1 phosphate receptor modulators, mixed polymers, NF-κB inhibitor, pyrimidine synthesis
inhibitor, monoclonal antibodies, corticosteroids, adrenocorticotropic hormone, and others. The
interferon beta segment accounted for a major share of the multiple sclerosis drugs market in 2018.
Interferon beta is a cytokine in the interferon family that is used to treat multiple sclerosis. Interferons
are proteins produced by the human body.
Interferon beta drugs include Avonex, Betaseron, Extavia, Rebif, and Plegridy. However, the monoclonal
antibodies segment is expected to dominate the multiple s